Provided by Tiger Fintech (Singapore) Pte. Ltd.

COLLPLANT BIOTECHNOLOGIES LTD

2.22
+0.01000.45%
Volume:5.44K
Turnover:11.93K
Market Cap:25.43M
PE:-1.53
High:2.27
Open:2.15
Low:2.15
Close:2.21
Loading ...

CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies

PR Newswire
·
15 Apr

When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven?

Simply Wall St.
·
28 Mar

Collplant Biotechnologies Is Maintained at Buy by D. Boral Capital

Dow Jones
·
27 Mar

CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

GuruFocus.com
·
27 Mar

CollPlant Biotechnologies FY 2024 GAAP EPS $(1.45) Misses $(1.44) Estimate, Sales $515.000K Miss $1.640M Estimate

Benzinga
·
26 Mar

Press Release: COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

Dow Jones
·
26 Mar

Collplant Biotechnologies Ltd expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
24 Mar

CollPlant expands distribution for its VergenixSTR product in Europe and Asia

TIPRANKS
·
24 Feb

CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia

PR Newswire
·
24 Feb

Collplant Biotechnologies Is Maintained at Buy by D. Boral Capital

Dow Jones
·
12 Feb

CollPlant grants AbbVie exclusive rhCollagen technology license

TIPRANKS
·
12 Feb

CollPlant to reduce workforce by 20%

TIPRANKS
·
12 Feb

Collplant Biotechnologies Is Maintained at Buy by D. Boral Capital

Dow Jones
·
04 Feb

Collplant Biotechnologies Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Nov 2024

CollPlant initial breast implant data ‘encouraging,’ says H.C. Wainwright

TIPRANKS
·
29 Nov 2024

Collplant Biotechnologies Ltd reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
27 Nov 2024

Collplant Biotechnologies Is Maintained at Buy by D. Boral Capital

Dow Jones
·
27 Nov 2024

CollPlant Biotechnologies Eyes Market with Innovative Implants

TIPRANKS
·
27 Nov 2024

Collplant Biotechnologies' Cash And Cash Equivalents As Of September 30, 2024 Were $15.4M, Expected To Provide Cash Runway Until The End Of 2025

Benzinga
·
27 Nov 2024

CollPlant Biotechnologies Q3 2024 Adj EPS $(0.33) Misses $(0.28) Estimate, Sales $4.00K May Not Be Comparable To $416.00K Estimate

Benzinga
·
27 Nov 2024